Pilar G. C.
- Country
- Spain
- Department
- ES30013: Oncologia Medica
Research Overview
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
- Pharmacokinetics, Safety, and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Gaucher Disease Types 1 and 3: A Multicenter Study
- A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors
Data & Insights
Has run more than one trial at 88 of 230 partner sites.
Specializations
Myeloproliferative Disorders
The investigator specializes in treating various myeloproliferative conditions, with particular focus on myelofibrosis and its subtypes including post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Their expertise extends to polycythemia vera management.
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
Rare Diseases
The investigator has developed expertise in treating rare genetic disorders, particularly focusing on Gaucher disease and Fabry disease. Their work encompasses both adult and pediatric populations affected by these conditions.
- Gaucher Disease Type 1
- Gaucher Disease Type 3
- Fabry Disease Management
Mast Cell Disorders
The investigator has dedicated research interest in various mast cell-related conditions, including indolent systemic mastocytosis and different forms of mast cell activation syndrome.
- Systemic Mastocytosis
- Monoclonal Mast Cell Activation Syndrome
- Non-Monoclonal Mast Cell Activation Syndrome
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.